Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Receivables - Net (2017 - 2026)

Neurocrine Biosciences filings provide 16 years of Receivables - Net readings, the most recent being $686.8 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 43.35% to $686.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $686.8 million, a 43.35% increase, with the full-year FY2025 number at $686.8 million, up 43.35% from a year prior.
  • Receivables - Net hit $686.8 million in Q4 2025 for Neurocrine Biosciences, down from $728.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $728.0 million in Q3 2025 to a low of $147.8 million in Q1 2021.
  • Median Receivables - Net over the past 5 years was $404.7 million (2023), compared with a mean of $394.6 million.
  • Biggest five-year swings in Receivables - Net: dropped 0.54% in 2021 and later soared 88.68% in 2022.
  • Neurocrine Biosciences' Receivables - Net stood at $185.5 million in 2021, then soared by 88.68% to $350.0 million in 2022, then rose by 25.51% to $439.3 million in 2023, then grew by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025.
  • The last three reported values for Receivables - Net were $686.8 million (Q4 2025), $728.0 million (Q3 2025), and $595.7 million (Q2 2025) per Business Quant data.